# US 10,444,239 B2 · Methods for measuring carcinoembryonic antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,444,239 B2
- Document ID: US10444239B2
- Status: Granted
- Kind: B2
- Application number: 15/147,960
- Filed: 2016-05-06
- Published: 2017-03-30
- Granted: 2019-10-15
- Earliest claimed: 2012-11-30
- Assignees: Interpace Diagnostics Corporation
- Applicants: Interpace Diagnostics Corporation
- Inventors: Sydney David Finkelstein; Sara Ann Jackson; Jamie Michelle Bleicher; Eric Matthew Gayle Ellsworth; Dennis Morgan Smith, Jr.
- Web page: https://patentgrep.com/patent/US10444239B2

## CPC

- G01N 33/57565: {involving carcinoembryonic antigen [CEA]}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are methods of accurately measuring carcinoembryonic antigen in a biological sample and methods of identifying and treating a mucinous cyst in a subject.

## Claims

### Claim 1

A method of measuring carcinoembryonic antigen in a biological sample, the method comprising:
diluting the biological sample with a diluent at a ratio of biological sample to diluent of about 1:10 to about 1:50 to form a diluted biological sample;
measuring the amylase level of the diluted biological sample; and
measuring carcinoembryonic antigen level in the diluted biological sample,
wherein the measured carcinoembryonic antigen amount is not adjusted with a correction factor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the diluent is saline, Diluent Universal, or a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological sample is undiluted prior to the diluting step.

### Claim 4 (depends on 1)

The method of claim 1, wherein diluting the biological sample with a diluent comprises diluting the biological sample with a diluent in a ratio of about 1:10.

### Claim 5 (depends on 1)

The method of claim 1, wherein diluting the biological sample with a diluent comprises diluting the biological sample with a diluent in a ratio of about 1:40.

### Claim 6 (depends on 1)

The method of claim 1, wherein the biological sample is not present in sufficient volume to accurately measure carcinoembryonic antigen level prior to the diluting step.

### Claim 7 (depends on 1)

The method of claim 1, wherein the biological sample has a high viscosity prior to the diluting step.

### Claim 8 (depends on 7)

The method of claim 7, wherein the high viscosity is due to the presence of mucin in the biological sample.

### Claim 9 (depends on 1)

The method of claim 1, wherein the carcinoembryonic antigen levels in the biological sample exceed the measurement capabilities of an instrument being used to measure carcinoembryonic antigen level prior to the diluting step.

### Claim 10 (depends on 1)

The method of claim 1, wherein the biological sample is selected from pancreatic fluid, pancreatic cyst fluid and combinations thereof.